Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
…, O Benjamini, Israeli CLL Study Group - Blood, The Journal …, 2022 - ashpublications.org
… This study evaluated the serologic response to a third BNT162b2 mRNA vaccine dose in
patients with CLL/SLL who had failed to respond to the standard 2-dose vaccination program. …
patients with CLL/SLL who had failed to respond to the standard 2-dose vaccination program. …
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
… patients who completed their treatment and remained in response at the time of vaccination
… Our results also suggest that a second timely vaccine dose is necessary for patients with …
… Our results also suggest that a second timely vaccine dose is necessary for patients with …
Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL
O Benjamini, R Gershon, E Bar‐Haim… - European Journal of …, 2023 - Wiley Online Library
… vaccine dose was evident in 55% of patients with CLL and 100% in age matched controls.
Titers increased by 10-fold in patients with CLL… after previous vaccinations, neutralizing assay, …
Titers increased by 10-fold in patients with CLL… after previous vaccinations, neutralizing assay, …
The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)
JA Whitaker, SA Parikh, TD Shanafelt, NE Kay… - Vaccine, 2021 - Elsevier
… to vaccination strategies in patients with hematologic malignancy, including those with CLL,
… Previous reports suggesting poor immunogenicity among patients with CLL receiving SD …
… Previous reports suggesting poor immunogenicity among patients with CLL receiving SD …
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
LE Roeker, DA Knorr, MC Thompson, M Nivar… - Leukemia, 2021 - nature.com
… We examined 44 consecutive patients with CLL who received two doses of mRNA vaccine
(… and laboratory parameters prior to first dose of COVID-19 vaccine were collected. Logistic …
(… and laboratory parameters prior to first dose of COVID-19 vaccine were collected. Logistic …
Vaccination efficacy in patients with chronic lymphocytic leukemia
… Pooled seropositivity rates were 51% in 1446 patients with CLL after 2 doses of the vaccine
[… rate after two doses of the COVID-19 vaccines was in the CLL population [Citation72]. Most …
[… rate after two doses of the COVID-19 vaccines was in the CLL population [Citation72]. Most …
Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
M Palma, L Adamson, L Hansson, P Kokhaei… - Cancer Immunology …, 2008 - Springer
… two patients received five doses of vaccines whereas the next ten patients received eight
doses of vaccines… Minor decreases in CD19+/CD5+ leukemic cells in five patients was noted as …
doses of vaccines… Minor decreases in CD19+/CD5+ leukemic cells in five patients was noted as …
Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia
CN Kontandreopoulou, EE Solomou, E Kolorizos… - Annals of …, 2024 - Springer
… programs have accelerated in several countries, many patients with CLL received a third
dose of vaccine. Results were extracted from eight studies meeting our criteria, providing data …
dose of vaccine. Results were extracted from eight studies meeting our criteria, providing data …
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
Y Shen, JA Freeman, J Holland, K Naidu… - Blood, The Journal …, 2022 - ashpublications.org
… T-cell function analysis in patients with CLL after multiple vaccination doses. The IFN-γ
and IL-2 responses were tested against the Miltenyi spike peptide pool. The mean number of …
and IL-2 responses were tested against the Miltenyi spike peptide pool. The mean number of …
Patients with chronic lymphocytic leukemia have a very high risk of ineffective response to the BNT162b2 vaccine
A Galitzia, L Barabino, R Murru, G Caocci, M Greco… - Vaccines, 2022 - mdpi.com
… , the impact of repeated doses on antibody response is still unclear in these patients and, in
… in 42 CLL patients after two mRNA vaccine doses and subsequently the role of a third dose. …
… in 42 CLL patients after two mRNA vaccine doses and subsequently the role of a third dose. …
相关搜索
- cell chronic lymphocytic leukaemia vaccinated patients
- third dose patients with cll
- vaccine dose cellular and humoral response
- vaccine doses immune responses
- covid 19 vaccination in patients
- acute lymphoblastic leukemia influenza vaccine
- recombinant herpes zoster vaccine in patients
- h1n1 pdm09 vaccine in patients
- sars cov 2 vaccination cll patients
- high dose influenza vaccine
- vaccines in patients variants of concern
- vaccine dose bnt162b2 mrna covid
- bnt162b2 mrna covid patients with cll
- treatment selection patients with cll
- influenza virus vaccination leukaemia patients
- high dose trivalent inactivated influenza vaccine